INSERT INTO sites(host) VALUES('coreynahman.com') 1045: Access denied for user 'www-data'@'localhost' (using password: NO) coreynahman.com Estimated Worth $76,234 - MYIP.NET Website Information
Welcome to MyIP.net!
 Set MYIP as homepage      

  
           

Web Page Information

Title:
Meta Description:
Meta Keywords:
sponsored links:
Links:
Images:
Age:
sponsored links:

Traffic and Estimation

Traffic:
Estimation:

Website Ranks

Alexa Rank:
Google Page Rank:
Sogou Rank:
Baidu Cache:

Search Engine Indexed

Search EngineIndexedLinks
 Google:
 Bing:
 Yahoo!:
 Baidu:
 Sogou:
 Youdao:
 Soso:

Server Data

Web Server:
IP address:    
Location:

Registry information

Registrant:
Email:
ICANN Registrar:
Created:
Updated:
Expires:
Status:
Name Server:
Whois Server:

Alexa Rank and trends

Traffic: Today One Week Avg. Three Mon. Avg.
Rank:
PV:
Unique IP:

More ranks in the world

Users from these countries/regions

Where people go on this site

Alexa Charts

Alexa Reach and Rank

Whois data

Who is coreynahman.com at com.whois-servers.net

Domain Name: COREYNAHMAN.COM

Registry Domain ID: 2704621_DOMAIN_COM-VRSN

Registrar WHOIS Server: whois.networksolutions.com

Registrar URL: http://networksolutions.com

Updated Date: 2014-12-08T22:30:32Z

Creation Date: 1998-12-09T05:00:00Z

Registry Expiry Date: 2024-12-08T05:00:00Z

Registrar: Network Solutions, LLC.

Registrar IANA ID: 2

Registrar Abuse Contact Email: abuse

Registrar Abuse Contact Phone: +1.8003337680

Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited

Name Server: a.ns.interland.net

Name Server: b.ns.interland.net

Name Server: c.ns.interland.net

DNSSEC: unsigned

URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/

>>> Last update of whois database: 2017-11-13T04:59:06Z <<<



For more information on Whois status codes, please visit https://icann.org/epp



NOTICE:
The expiration date displayed in this record is the date the

registrar's sponsorship of the domain name registration in the registry is

currently set to expire. This date does not necessarily reflect the expiration

date of the domain name registrant's agreement with the sponsoring

registrar. Users may consult the sponsoring registrar's Whois database to

view the registrar's reported date of expiration for this registration.



TERMS OF USE:
You are not authorized to access or query our Whois

database through the use of electronic processes that are high-volume and

automated except as reasonably necessary to register domain names or

modify existing registrations; the Data in VeriSign Global Registry

Services' ("VeriSign") Whois database is provided by VeriSign for

information purposes only, and to assist persons in obtaining information

about or related to a domain name registration record. VeriSign does not

guarantee its accuracy. By submitting a Whois query, you agree to abide

by the following terms of use: You agree that you may use this Data only

for lawful purposes and that under no circumstances will you use this Data

to:
(1) allow, enable, or otherwise support the transmission of mass

unsolicited, commercial advertising or solicitations via e-mail, telephone,

or facsimile; or (2) enable high volume, automated, electronic processes

that apply to VeriSign (or its computer systems). The compilation,

repackaging, dissemination or other use of this Data is expressly

prohibited without the prior written consent of VeriSign. You agree not to

use electronic processes that are automated and high-volume to access or

query the Whois database except as reasonably necessary to register

domain names or modify existing registrations. VeriSign reserves the right

to restrict your access to the Whois database in its sole discretion to ensure

operational stability. VeriSign may restrict or terminate your access to the

Whois database for failure to abide by these terms of use. VeriSign

reserves the right to modify these terms at any time.



The Registry database contains ONLY .COM, .NET, .EDU domains and

Registrars.

Front Page Thumbnail

sponsored links:

Front Page Loading Time

Keyword Hits (Biger,better)

Other TLDs of coreynahman

TLDs Created Expires Registered
.com
.net
.org
.cn
.com.cn
.asia
.mobi

Similar Websites

More...
Alexa鏍囬

Search Engine Spider Emulation

Title:Pharmaceutical News And Information - InternetDrugNews.com
Description:Pharmaceutical News And Information Updated Daily Since 1998
Keywords:Pharmaceutical News And Information
Body:
Pharmaceutical News And Information - InternetDrugNews.com
Internet Drug News.com Pharmaceutical News amp; Information; Updated Daily
map


Research/Regulatory
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus by Topic
Amedeo
Viagra
CDER LIst - (FDA)
Gen Info;Site Dissectionfont
Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug Approvals.org
Dear Doctor Letter Database
Drugs@FDA #91;gateway #93;
Drug Approvals Report
Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings
Medwatch Safety
Recalls/Alerts
NDC Code Directory
Postmarketing Safety Data
Warning Letters
Medwatch
Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales
Search By Definition
We comply with the HONcode standard for trustworthy health information: verify herea.
***********
Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- NewHopeBlog.com
- Drug Wonks
- World Of DTC Marketing.com
驴Your Link Here?
Let's Trade








Pharmaceutical News Harvest (TM)8/8 Fast TakesDEA proposes cutting production of some opioid painkillersReutersWhy Eli Lilly Has the Strongest Reputation in the Life Sciences IndustryBioSpaceFalling U.S. Generic Drug Prices Hurt Manufacturers, WholesalersWSJThe generic drug bloodbath continues for a second day, with Teva leading the wayMarket WatchIn North Carolina, "heroin is more accessible and cheaper than alcohol"Salon10 Reasons Cancer Drugs Usually Cost $100,000 or More a YearMotley Fool
map


8/8 FDA Boss Threatens To Publicly Shame Certain Drugmakers - Refusing to turn over samples of brand meds needed to approve genericsDrug makers deserve to be publicly shamed for thwarting competition from generics 鈥 generic drug makers have bitterly complained that brand-name companies hide behind REMS programs in order to deny them samples 鈥 #91;Pharmalot FREE #93;How do you get lower cost drugs? Give the FDA a bigger stick 鈥 Generics must get a sample of the brand name drug they want to ... FDA currently does not have the tools necessary to discipline these bad actors and force the distribution of samples to generic companies 鈥 #91;The Hill #93;8/8 How Much Would You Pay To Live Free? OR Why Opiates Are Such a Good Deal?How much would you pay to live pain-free? 鈥 The answer: between $56 and $145. A day. Which works out to between $20,000 and $53,000 a year 鈥 Along comes a product that offers the promise of doing that for less than 1/100th of that price. What are you going to do? 鈥 #91;Washington Post #93;8/8 United Healthcare: No More Sharing Sexual Secrets To Get HIV Pills- Patients were denied HIV prevention pills if they confessed to certain sexual practices United Healthcare does an about-face on an 'egregious' policy for an HIV drug 鈥 restricted access to an HIV prevention drug, which could only be obtained after patients completed enrollment forms asking about high-risk sexual behavior 鈥 #91;Pharmalot #93;UnitedHealthcare denied PrEP coverage to gay man for 'high risk homosexual behavior 鈥 information sent in shows you are using this medicine for engaging in High risk homosexual behavior," reads the letter on Unitedhealthcare letterhead posted on a Facebook site frequented by people impacted by HIV/AIDS. "This determination is considered to be a determination that the requested coverage is not medically necessary 鈥 #91;Los Angeles Blade #93;8/8 GSK CEO: Outsider's Lack Of Loyalties Is AssetGSK chief says her lack of 'baggage' in pharma is an advantage 鈥 Recruited seven years ago from L'Or茅al, she is an outsider in a company with a pronounced internal culture 鈥 although GSK has secured a high volume of drug approvals it has significantly lagged behind its peers in peak-year sales for each asset 鈥 #91;FT #93;New CEO Emma Walmsley shows she is not afraid to ruffle feathers at GSK 鈥 "fresh pair of eyes" was incredibly helpful when deciding which therapy areas to invest in or in making personnel decisions. 鈥 #91;Pharma Letter #93;8/8 CVS Formulary Position Locked In, Allergan Goes All In With Rosacea CreamAllergan ramps up promotion for new rosacea drug 鈥 Allergan told investors it plans to increase its promotional efforts for its new rosacea drug, Rhofade, now that it has secured access on CVS Health #39;s formulary 鈥 began advertising on Facebook last week and will ramp up other aspects of its consumer-advertising 鈥 #91;MM amp;M #93;********* Worth A Click/Tap **********Pharma Bro Martin Shkreli's Live YouTube Feed : Shkreli comments on his case, debates haters, tells his side of the story, plays video games, ************************************8/8 Specialty Pharma: Mallinckrodt Goes Shopping In Baby Care IsleMallinckrodt snaps up pediatric jaundice drug 鈥 Stannsoporfin has fast track status for the treatment of severe jaundice in high-risk newborns 鈥 applied for approval in the U.S. under a rolling New Drug Application process. Approval is expected in the first half of 2018 鈥 #91;BioPharma Dive #93;8/7 Fast TakesEli Lilly's new, $1B pain drug racks up another promising round of PhIII pain dataEndpoints NewsExpress Scripts shuts out 64 branded drugs from 2018 formularyBioPharma DiveCVS Health removes 17 drugs from formulary, adds outcomes-based programBioPharma DiveTrump to Ink FDA User Fee Bill, Saving 5,000 JobsBioSpaceShire may spin off hyperactivity drugs, raises forecastsReutersFDA panel votes against approval of J amp;J arthritis drug irukumab on safety concernsReuters8/7 WSJ: PBMs Push Brand Name Epi-Pens Despite Availability Of Cheaper GenericBehind the Push to Keep Higher-Priced EpiPen in Consumers' Hands 鈥 Despite availability of generic version, the brand-name allergy drug still takes a big share of the market; the complex role of middlemen 鈥 to the extent that the PBM retains a portion of the rebates and back end incentives, they would stand to gain from dispensing the brand 鈥 #91;WSJ #93;8/7 NY Times: Back Room Deals Lead PBMs To Push Brand Name Meds- Can your insurance company forces you to avoid the generic? Yes It CanTake the Generic, Patients Are Told. Until They Are Not. 鈥 Lisa Hopkins of Eagleville, Pa., was required to buy the brand-name anti-inflammatory gel Voltaren, rather than the cheaper generic 鈥 Out of public view, corporations are cutting deals that give consumers little choice but to buy brand-name drugs -- and sometimes pay more at the pharmacy counter than they would for generics. 鈥 #91;NY Times #93;8/7 New Data: Banning Reps Had No Effect On Blunting Demand- Pharma largesse had little influence on choosing cancer drug despite conventional wisdomCan Pharma Influence Physician Prescribing? Unleashing New Data Using Prostate Cancer Drugs 鈥 pen that is formed into an erect penis is not enough to make me write for Cialis 鈥 In fact, the median amount of prescribed drugs was exactly the same between those doctors who received money from the pharmaceutical companies and those that did not 鈥 #91;Forbes #93;8/7 AbbVie's New Hepatitis Pill Poised To Disrupt Gilead Market DominanceLook out Gilead, AbbVie's hep C combo comes with stellar data, 8-week regimen and a killer price 鈥 In other words, look out Gilead 鈥 payers will have no problem cheering the price war that AbbVie clearly wants to start 鈥 #91;Endpoints News #93;8/7 Pharma Bro Shkreli Found Guilty Of Fraud- Faces jail time, acquitted of serious charges- Unrepentant former pharma CEO predicts light sentenceMartin Shkreli Is Found Guilty of Fraud 鈥 lawyers focused on the fact that his investors ultimately made back much more than their initial investments. They said that was proof that Mr. Shkreli had never intended to commit fraud 鈥 #91;NY Times #93;8/7 Hepatitis Vaccine Faces Extended Review But Company Execs Confident Of ApprovalFDA extends review on Dynavax #39;s Heplisav-B, but management remains confident 鈥 aiming to launch the shot, a challenger to GlaxoSmithKline's Engerix-B, in the U.S. in early 2018. It #39;s proposing to conduct the phase 4 study in collaboration with Kaiser 鈥 #91;Fierce Pharma #93;Dynavax Shares Plunge on Delayed FDA Decision for Hep B Vaccine Heplisav 鈥 #91;BioSpace #93;8/7 Big Chains Play Hardball With Generic DrugmakersWal-Mart, Walgreens, CVS turn up the heat on generic drugmaker deals 鈥 wielding more leverage when buying generic drugs, accelerating a decline in prices likely to affect drug companies for some time 鈥 these guys are getting much better pricing and really squeezing the manufacturers #91;of generic drugs #93; on margins, quot; 鈥 #91;Reuters #93;8/7 Renegeron Announcement: Decade Old Partnership With Sanofi To EndRegeneron beats profit view, to end antibody deal with Sanofi 鈥 expiration of the antibody discovery agreement would not impact the agreement covering Praluent, Dupixent and Kevzara 鈥 deal provided the U.S. drugmaker with over $1 billion in R amp;D 鈥 #91;Reuters #93;
8/4
FDA User Fee Bill Passes Senate; Trump Will Sign; Effective for Five Years
Trump to Sign FDA User Fee Reauthorization Bill
....
Ahead of its summer recess, the US Senate has followed its House counterparts and passed a bipartisan bill to reauthorize the US Food and Drug Administration user fee programs for prescription drugs, generic drugs, medical devices and biosimilars for the next five years
....
Endpoints
8/4
Mavyret Approved; First 8-Week Treatment for All Hep C Genotypes
FDA approves AbbVie's hepatitis C drug
....
Mavyret aims to treat hepatitis C genotypes 1 through 6 in previously untreated adults with or without mild cirrhosis, a type of liver disease, including patients with moderate to severe kidney disease and those on dialysis
....
Reuters
AbbVie says new HepC drug Mavyret to cost $26,400 a patient for 8-week treatment, most common duration $ABBV mdash; Peter Loftus (@Loftus) August 3, 2017
8/4
Vyxeos Approved; Daunorubicin/Cytarabine Combination Extends OS 3.6 Months vs. Separate Administration
Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M amp;A next?
....
As fixed-dose combination of two chemotherapy drugs, daunorubicin and cytarabine, Vyxeos might seem to be one of those combination drugs that has a difficult time winning payer coverage. That may prove to be true, but the FDA says the Jazz formula actually has life-prolonging benefits over taking the two chemotherapies alone
....
Fierce Pharma
8/4
'Right-to-Try' Has Friends in High Places
Senate approves 'right-to-try' drug bill
....
Sen. Ron Johnson's measure, S. 204 (115), would authorize the use of unapproved medicines by patients diagnosed with a life-threatening illness as long as the drugs in question have already gone through preliminary testing on humans and continue to be evaluated in research the FDA oversees
....
Politico
8/4
Copaxone Sales Declines, Generics Pricing Pressures Send Teva in a Tailspin
Embattled Teva slashes staff, manufacturing facilities
....
The Israeli company will have 7,000 fewer staff members by the end of 2017 since closing of the Actavis generics business and will exit 45 markets globally. The company intends to close or divest 15 manufacturing plants by the end of 2018
....
Biopharma Dive
8/4
More PBM Formulary Maneuvers Coming in September
Pharma's Quieter Price War Continues
....
There's still more bad news to come for drugmakers. Both Express Scripts and CVS will provide formulary updates (and possible additional drug exclusions) in mid-September on two of the biggest disease categories: autoimmune blockbusters such as Humira and Remicade, and medicines for Hepatitis C. In the latter category, PBMs have already wrung big discounts out of drugmakers, and competing medicines will be available soon.
....
Bloomberg
8/4
Shire's Rare Disease Focus Points to Company Split
Shire may spin off hyperactivity drugs, raises forecasts
....
Chief Executive Flemming Ornskov said the recent approval of its newest ADHD drug, and strong demand for its blockbuster Vyvanse, meant the business could thrive as a standalone company
....
Reuters
8/4
Alkermes Finds a Route to Grow Vivitrol Sales from $30 Million to $206 Million
To Grow Market Share, A Drugmaker Pitches Its Product To Judges
....
Some drug courts offer participants a full range of evidence-based treatment, including medication-assisted treatment. Others don't allow addiction medications at all. And some permit just one: Vivitrol
....
NPR Shots Blog
8/4
Antiretroviral Therapy May Shift to Injections (from Daily Pills)
New injectable antiretroviral treatment proved to be as effective as standard oral therapy
....
After 96 weeks, researchers found that 87 percent of patients in the group treated every four weeks and 94 percent in the group treated every eight weeks maintained viral load suppression, greater than the standard oral treatment group at 84 percent
....
Medical Xpress
8/4
Opdivo for Certain Colorectal Cancers
Opdivo Receives New Indication for MSI-H or dMMR Colorectal Cancer
....
The objective response rate (ORR) as assessed by an independent radiographic review committee using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria was 28% (n=15; 95% CI, 17, 42) in the 53 patients who received prior fluoropyrimidine, oxaliplatin and irinotecan. Responses lasted six or more months for 67% (95% CI, 38, 88) of patients
....
Specialty Pharmacy Continuum
8/4 Internet Drug News Fast Takes:
Regeneron beats profit view, to end antibody deal with Sanofi
Reuters
How Do Docs Learn About New Drugs? TV, Of Course
MM amp;M
Bristol-Myers to buy IFM Therapeutics for $300 million, and potential contingent payments
Marketwatch
Short Answers to Hard Questions About the Opioid Crisis
NY Times
Depression: How to treat, avoid misdiagnosis
Managed Healthcare Executive
map



8/3
New CVS Formulary Goes Value-Based
CVS Health removes 17 drugs from formulary, adds outcomes-based program
....
CVS Health looks set to change the game once again with an outcomes-based management program that will specifically target drugs for breast cancer, non-small cell lung cancer (NSCLC), obesity and chronic obstructive pulmonary disease (COPD).... manufacturers will have to cover costs over a pre-specified threshold if patients don't reach certain outcomes
....
BioPharma Dive
8/3
Advisors Vote Down Sirukumab
FDA experts turn thumbs down on J amp;J's troubled rheumatoid arthritis drug sirukumab
....
The vote was 12 to 1 against the drug, saying that the safety profile did not justify an OK. That was the key issue, and they followed up by the same numbers in a formal vote against an approval
....
Endpoints
8/3
First Successful Gene Mutation Fix
U.S. scientists able to alter genes of human embryos
....
Oregon Health and Science University (OHSU) collaborated with the Salk Institute and Korea's Institute for Basic Science to use a technique known as CRISPR-Cas9 to correct a genetic mutation for hypertrophic cardiomyopathy
....
Reuters
8/3
25,000 Person Study to Find Roots of Depression in DNA
23andMe, Lundbeck unveil mega investigation of genetics' role in depression
....
Study participants are required to provide their DNA through a saliva sample, then complete monthly surveys and cognitive tests on a desktop or laptop
....
BioPharma Dive
8/3
Volume Growth in Medicines is Almost All in Developing World; So Pharma is Building Inroads
Drug Giants Are Hunting for Patients in India's Remote Corners
....
First, foreign food brands flooded India with chips, cookies and soft drinks that fundamentally changed the nation's eating habits. Now, Big Pharma wants to cash in on an upsurge in cases of diabetes and heart disease in the country's most distant corners
....
Bloomberg
8/3
Rules Set for OTC Monograph Program
FDA Details Draft Goals for OTC Monograph User Fee Program
....
The goals letter lays out a framework for two tiers of industry submitted OTC monograph order requests (OMORs), timelines for their review and FDA's performance commitments for completing those reviews. The letter also establishes specific goals for staff and infrastructure enhancements for the agency to meet those goals
....
Regulatory Focus
8/3
Millions of Unsecured, Excess Opioids Sitting in Peoples' Medicine Chests
Study adds to evidence that most prescribed opioid pills go unused
....
In a review of half a dozen published studies in which patients self-reported use of opioids prescribed to them after surgery, researchers at Johns Hopkins report that a substantial majority of patients used only some or none of the pills, and more than 90 percent failed to dispose of the leftovers in recommended ways
....
Medical Xpress
8/3
HHS Sec. Tom Price Rolling Back Obama-Era Doc Regulations
With Tom Price in charge, doctors are winning again in Washington
....
Quietly, away from the spotlight cast on his effort to dismantle Obamacare, Price has been rolling back regulations that have been criticized by his former physician colleagues. And, unlike with the ACA, he has been able to do so without the blessing of Congress
....
Stat
8/3
State-Run Drug Price Websites Inconsistent
Availability and Variation of Publicly Reported Prescription Drug Prices
....
Publicly reported information on state prescription drug price websites is often deficient. When prices are reported, there can be significant variation in the prices of prescriptions, which could translate into substantial savings for consumers who pay out-of-pocket for prescription drugs
....
AJMC
8/3
Imbruvica Gets New Indication
J amp;J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
....
The FDA has approved the product for chronic graft-versus-host disease (cGVHD), marking the first time it's green-lighted any med in that area. Imbruvica bears a second-line nod, meaning patients need to have failed on one or more treatments鈥攕uch as corticosteroids mdash;before receiving it
....
Fierce Pharma
8/3 Internet Drug News Fast Takes:
Autism may reflect excitation-inhibition imbalance in brain
Medical Xpress
UK finds Roche bladder cancer drug Tecentriq too costly for routine use
Reuters
Vertex Pharma Kalydeco Approved for CF Patients With Certain Residual Function Mutations
Company News Release
Americans Die Younger Despite Spending the Most on Health Care
Bloomberg
New System Speeds FDA Import Decisions
FDA Blog
8/2
CVS Releases 2018 National Formulary
CVS 2018 Formulary Strategy
....
Jardiance, Synjardy/Synjardy XR out; Invokana, Invokamet/Invokamet XR back in
....
CVS (h/t @drugchannels)
8/2
Idhifa Approved for Acute Myeloid Leukemia with Specific Mutation; Black Box
FDA approves leukemia treatment developed by Celgene, Agios
....
Idhifa is the first and only FDA-approved therapy for patients with an IDH2 mutation, a group that accounts for 8 to 19 percent of all AML patients. In the United States, that translates to about 1,200 to 1,500 patients
....
Reuters
$CELG tells me U.S. Idhifa monthly wholesale acquisition cost is $24,872. Notes 1,200-1,500 patients in U.S.; median time on therapy 4.3 mos mdash; Meg Tirrell (@megtirrell) August 1, 2017
8/2
Part B Spending Shift to Hospital Outpatient Facilities
New Part B Buy-and-Bill Data: Physician Offices Are Losing to Hospital Outpatient Sites
....
Hospital outpatients' share of Part B spending has grown from 21% in 2005 to 34% in 2015
....
Drug Channels
8/2
Preeclampsia on the Rise
Pregnancy disorder exacts toll on mothers, babies, healthcare funds
....
A little-understood syndrome likely afflicted nearly 157,000 pregnant women and new mothers in the United States in 2012, killed 72 of them, and cost the U.S. healthcare system more than $2 billion
....
Reuters
8/2
Opdivo ndash;Rubraca Combo Tests
Bristol-Myers and Clovis will partner for cancer combination trials
....
Under the partnership, the two drugs will be tested in late-stage clinical trials for advanced ovarian cancer and advanced breast cancers, and in a mid-stage clinical trial for prostate cancer, all of which are expected to start before the end of the year
....
MarketWatch
8/2
Why Does Spinraza Cost So Much? mdash; Covered Families Unable to Afford Even the $2000 Injection Fees for $750,000/Year Drug
Drug Puts A $750,000 'Price Tag On Life'
....
If just half of U.S. patients get treatment for one year, the tab would be more than $3.7 billion. Spinraza brought in $203 million in the second quarter of this year, more than four times its revenue in the first quarter
....
Kaiser Health News/NPR
8/2
Senate Will Vote on FDA Bill Before Recess; Unclear if President Will Insist on 100% Industry Funding
Senate to Finish FDA User Fee Reauthorization Bill Ahead of Summer Recess
....
President Donald Trump urged Congress in July to overhaul the agreements forged by FDA and industry, and entirely fund the agency with user fees. Such an overhaul, first discussed in Trump's budget proposal in May, has been rejected by members on both sides of the aisle, though it remains unclear if Trump would veto the bill if Congress does not accept his proposal.
....
Regulatory Focus
8/2
Pfizer Reports Q2 Results; Sales Down, But Pipeline Strong
Despite blockbuster boasts for R amp;D work, pressure increases on Pfizer to do a megadeal
....
Pfizer is already one of the top R amp;D spenders in the business, and this year expects to spend upwards of $8 billion on new drug development.... the company boasted of 25 to 30 potential approvals over the next 5 years, including 15 "possible blockbusters"
....
Endpoints
8/2
Allergan's Migraine Meds Expected in 2020 and 2022
Unfazed by competition, Allergan sees room at CGRP table
....
The company has pushed the two CGRP inhibitors it acquired from Merck, ubrogepant and atogepant, into Phase 3 and Phase 2b studies, respectively. And the company believes it can carve out a multi-billion dollar opportunity of its own, counting on its past experience with migraine and the convenience factor of an oral pill
....
BioPharma Dive
8/2
Gritty Entrepreneur Finds Riches in Niches
Jonathan Ross Goodman (Knight Therapeutics) Rallies From Near-Death Bike Spill for Drug Renaissance
....
Goodman makes money by acquiring marketing rights to specialty drugs in countries deemed too small to be worth the trouble for multinational drug makers.... In 2016, Knight generated $4.4 million in sales, mostly from selling Movantik, an AstraZeneca treatment for opioid-caused constipation, and Impavido, a Paladin-developed treatment for leishmaniasis
....
Bloomberg
8/2
Running the Numbers on Sen. Sanders' "Buy from Canada" Bill
CBO: Americans would save $7B buying prescription drugs from Canada
....
In a statement announcing the bill's introduction, sponsor Sen. Bernie Sanders said that prescription drugs made by the same companies in the same factories are available in other countries for less than the price they're sold for in the United States
....
UPI
8/1 Internet Drug News Fast Takes:
Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo
Fierce Pharma
Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
Reuters
White House opioid commission to Trump: 'Declare a national emergency' on drug overdoses
Washington Post
Post-Brexit European Drugs Regulator Wooed by 19 Nations
Bloomberg
Hospitals tighten controls on health benefits amidst rising costs, changing industry landscape
Healthcare Finance
8/1
Who's In, Who's Out for Express Scripts 2018 National Formulary
Express Scripts adds 64 medications to its no-go list, hitting Lilly and Amgen but sparing diabetes
....
Synergy Pharmaceuticals didn't secure a favorable position for its new chronic idiopathic constipation entrant Trulance. After a January approval, that drugmaker priced its medication on par with Allergan's Linzess, at $353 per script, and just higher than Sucampo and Takeda's Amitiza, which costs $350. Those two medications will serve as Express Scripts' preferred choices for the upcoming year
....
Fierce Pharma
See also: Express Scripts to cover Mylan's EpiPen, exclude rivals [Reuters]
8/1
Dupixent On Track to Pass Cosentyx
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
....
Dupixent's script numbers are hovering between 1,500 and 1,600 in recent weeks, according to Leerink's latest prescriptions report. That's up from around 1,000 six weeks ago.... Prior-authorization approvals are running at 73% across all plans and 80% in plans where Dupixent coverage contracts are already in place
....
Fierce Pharma
8/1
Another Biosimilar for Herceptin
U.S. FDA to review Teva and Celltrion's cancer biosimilar drug
....
CT-P6, already approved by the Korean Ministry of Food and Drug Safety, is a biosimilar to Roche's breast cancer and gastric cancer treatment Herceptin. Earlier this month, an advisory panel to the FDA recommended approval of a Herceptin biosimilar from Mylan and Biocon
....
Reuters
8/1
Plug Pulled on Tanzeum
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca
....
Glaxo had tried to price its med at a discount to its GLP-1 rivals, but even those price breaks hadn't helped Tanzeum gain traction, Anderson noted. For 2017, leading PBM Express Scripts knocked Tanzeum off its preferred formulary, turning its spot over to Eli Lilly star Trulicity
....
Fierce Pharma
8/1
Imfinzi Gets Breakthrough
Durvalumab Granted Breakthrough Therapy Designation by FDA for NSCLC
....
The designation, which will expedite the development and review of durvalumab in this setting, is based on interim results from the phase III PACIFIC trial, in which the PD-L1 inhibitor significantly improved progression-free survival (PFS) compared with placebo
....
Targeted Oncology
8/1
FDA Reviewers Wave Red Flag on Sirukumab
FDA slams J amp;J's blockbuster contender sirukumab on 'important safety risks'
....
According to the review, there was a clear imbalance in deaths and malignancies among the patients studied over a 52-week period
....
Endpoints
8/1
Your Internet Radio Station Knows if You Have Diabetes
Personalization expert Pandora's pharma practice takes off after patient-data partnership
....
The music streaming and recommendation engine has more than 2,000 different audience segments, including more than 100 specific to health conditions such as allergies, headaches, diabetes or arthritis, as well as prescription drug categories
....
Fierce Pharma
8/1
'I Feel Your Pain,' Pharma Virtual Reality Edition
Drugmakers turn to tech to better demonstrate empathy
....
A recent Massachusetts General Hospital study found that 65% of patient satisfaction mdash; now linked to reimbursements in many cases mdash; is attributed to physician empathy.
....
MM amp;M
8/1
App-Based Delivery-Centered Pharmacy Launched
DC startup CaryRx hopes to disrupt prescription drug home delivery
....
CaryRx, a prescription drug delivery service that just launched in the Washington metro, thinks it can disrupt the drug delivery business by not delivering from your pharmacy, but by being the pharmacy itself
....
WTOP
8/1
Antidepressants, In Particular, Have Complicating Side Effects for Many
Site Map #124; Privacy Policy #124; Contact WebmasterSite Mission Statement, Intended Audience, Editorial Policy, Advertising PolicyThis Page Last Updated 8/07/2017If your intellectual property being infringee-mail the webmaster and we will fix it. The information on this site is not meant as medical advice. If you have any medical questions please consult your medical doctor or similar medical practitioner. The information contained on this web site is for your information only. Never take a drug without a doctor #39;s prescription - only an idiot does that. Do NOT give yourself any drug unless it has been prescribed for you by a doctor.Do NOT start or stop taking a medicine based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.Sincerely,Corey Nahman Licensed Pharmacist (State Of NY; Lic #35;035512)*****************************************We subscribe to The HONcode of online conduct:1. Qualification of author(s) This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.2. ComplementarityLet it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.3. Privacy.We respect the privacy of the users of this site. Please see our plain English privacy policy.4. AttributionAt all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.5. JustifiabilityThis site shall at all times back up claims relating to benefits and performance.6 TransparencyThis site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.7. Financial disclosureThis site is supported by click advertisements, banner advertisements and affiliate arrangements. All ads are properly labeled as such. If you have any questions regarding how we make money please e-mail the webmaster with your questions. All advertisements shall be clearly distinguished from content.Badea, Badea, Badea, That's All Folks!








Updated Time

Updating   
Friend links: ProxyFire    More...
Site Map 1 2 3 4 5 6 7 8 9 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 250 300 350 400 450 500 550 600 610 620 630 640 650 660 670 680 690 700 710 720 730 740 750
TOS | Contact us
© 2009 MyIP.cn Dev by MYIP Elapsed:84.813ms